← Back to Search

Mobile Health Application and Wearable Device

Mobile Health Technology for Colorectal Cancer Recovery

N/A
Recruiting
Led By Heather Yeo, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is scheduled to undergo surgery for a GI cancer (pancreatic, hepatic, gastric, small bowel, colon, or rectal cancers)
Subject speaks English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This trial will test if mobile devices can help prevent readmission in patients who have had major GI cancer surgery.

Who is the study for?
This trial is for English-speaking adults over 18 who own a smartphone and are scheduled for GI cancer surgery (pancreatic, liver, stomach, small bowel, colon or rectal). It's not suitable for those with dementia, substance abuse issues, sepsis from another source or needing emergency surgery.Check my eligibility
What is being tested?
The study compares the effectiveness of using mobile health apps and Fitbit alongside standard care versus standard care alone in preventing hospital readmission after major GI cancer surgeries.See study design
What are the potential side effects?
Since this trial involves non-invasive tools like mobile apps and Fitbit devices along with usual medical care, side effects may be minimal but could include discomfort or skin irritation from wearing the device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for surgery for a GI cancer.
Select...
I speak English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Readmission rate
Secondary outcome measures
Healthcare utilization rates
Patient Satisfaction with Device
Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs)
+1 more

Side effects data

From 2007 Phase 4 trial • 552 Patients • NCT00110890
7%
Diarrhoea
7%
Vomiting
3%
Nausea
3%
Nasopharyngitis
3%
Muscle spasms
1%
Pancreatic carcinoma
1%
Shunt thrombosis
1%
Angina pectoris
1%
Myocardial infarction
1%
Pericarditis
1%
Jaundice
1%
Shunt occlusion
1%
Gastroenteritis
1%
Hernia
1%
Chest discomfort
1%
Arteriovenous fistula thrombosis
1%
Skin ulcer
1%
Fluid retention
1%
Hypovolaemia
1%
Hypertensive crisis
1%
Cognitive disorder
1%
Joint dislocation
1%
Joint injury
1%
Blood potassium increased
1%
Catheter placement
1%
Arteriovenous fistula occlusion
1%
Orthostatic hypotension
1%
Cardiac arrest
1%
Chest pain
1%
Pyrexia
1%
Cholecystitis
1%
Arthritis bacterial
1%
Bacterial sepsis
1%
Fall
1%
Back pain
1%
Pain in extremity
1%
Dyspnoea
1%
Nephrectomy
1%
Hypotension
1%
Peripheral ischaemia
1%
Atrial flutter
1%
Cardiac asthma
1%
Abdominal pain
1%
Sudden cardiac death
1%
Transplant rejection
1%
Perianal abscess
1%
Pneumonia
1%
Urinary tract infection
1%
Ankle fracture
1%
Arteriovenous fistula site complication
1%
Rib fracture
1%
Cerebral infarction
1%
Gastrointestinal haemorrhage
1%
Catheter related infection
1%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Standard Care
Cinacalcet

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Standard of careExperimental Treatment1 Intervention
Participants will receive standard of care
Group II: Mobile app and Fitbit + Standard of careActive Control1 Intervention
Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,054 Previous Clinical Trials
1,316,212 Total Patients Enrolled
Damon Runyon Cancer Research FoundationOTHER
9 Previous Clinical Trials
1,038 Total Patients Enrolled
Heather Yeo, MDPrincipal InvestigatorWeill Medical College of Cornell University

Media Library

Mobile health application and Fitbit (Mobile Health Application and Wearable Device) Clinical Trial Eligibility Overview. Trial Name: NCT03623464 — N/A
Liver Tumors Research Study Groups: Standard of care, Mobile app and Fitbit + Standard of care
Liver Tumors Clinical Trial 2023: Mobile health application and Fitbit Highlights & Side Effects. Trial Name: NCT03623464 — N/A
Mobile health application and Fitbit (Mobile Health Application and Wearable Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03623464 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of research participants in this experiment?

"Affirmative. Clinicaltrials.gov reveals that recruitment is underway for this medical experiment, which was originally listed on May 31st 2017 and refreshed most recently on July 29th 2022. The clinical trial requires 316 participants to be gathered at 1 location."

Answered by AI

Are there still positions available for individuals interested in participating in this clinical trial?

"Affirmative. Data hosted on clinicaltrials.gov confirms this trial is currently recruiting individuals, having been first posted on May 31st 2017 and recently updated July 29th 2022. The study requires 316 participants from a single site to participate."

Answered by AI
~31 spots leftby Feb 2025